TITLE

Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer

PUB. DATE
January 2008
SOURCE
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a clinical study that evaluates whether the primary prophylactic use of granulocyte colony-stimulating factor (G-CSF) reduces febrile neutropenia and early mortality in adult patients with cancer. The study showed that the use of G-CSF reduced febrile neutropenia and short-term mortality during the chemotherapy period. It is also showed that the G-CSF increases dose intensity of delivered chemotherapy, but increases bone pain.
ACCESSION #
28694428

 

Related Articles

  • Pegfilgrastim for Chemotherapy-Induced Neutropenia. Bedell, Cindi // Clinical Journal of Oncology Nursing;Jan/Feb2003, Vol. 7 Issue 1, p55 

    Many chemotherapy regimens cause myelosuppression, which can result in febrile neutropenia and potentially lead to serious infections. The risk of neutropenia and its complications can be reduced with filgrastim, a granulocyteu colony-stimulating factor. Filgrastim is safe and effective, but it...

  • COMMENTARY: Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer. Frank, David A. // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p7 

    The author comments on the study that evaluates the relationship of primary prophylactic use of granulocyte colony-stimulating factor (G-CSF) in reducing febrile neutropenia and early mortality of patient with cancer. He pointed out that the study recognizing that the patients with comorbid...

  • Is pegfilgrastim appropriate for the treatment of established febrile neutropenia? Stanford, Brad L.; Zondor, Stacey D.; Cobos, Everardo // Journal of Oncology Pharmacy Practice;Sep2003, Vol. 9 Issue 2/3, p113 

    Objective. To report a case where both pegfilgrastim and filgrastim were considered in the treatment of febrile neutropenia in a hospitalized patient and assess the most cost-effective option. Case summary. A 77-year-old white female was diagnosed with squamous cell carcinoma of the anus and...

  • Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia. Advani, S. H.; Achreckar, Suvarna; Thomas, Dennis; Krishnankutty, Binny // Indian Journal of Medical & Paediatric Oncology;Jul-Sep2010, Vol. 31 Issue 3, p125 

    Background: The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for patients with chemotherapy-induced febrile...

  • Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. Ip, Eric J.; Lee-Ma, Annette; Troxell, Lawrence S.; Chan, James // American Journal of Health-System Pharmacy;8/15/2008, Vol. 65 Issue 16, p1552 

    Purpose. The objective of this study was to compare low-dose filgrastim (150 µg/day subcutaneously) with standard-dose subcutaneous filgrastim (300 µg/day) or lenograstim (263 µg/day) in preventing febrile neutropenia and hospitalizations in breast cancer patients receiving the...

  • Hematopoietic Support With Moderately Myelosuppressive Chemotherapy Regimens: A Nursing Perspective. Moore, Kelley; Crom, Debbie // Clinical Journal of Oncology Nursing;Jun2006, Vol. 10 Issue 3, p383 

    The proactive use of granulocyte--colony-stimulating factors (G-CSFs) in patients with cancer treated with chemotherapy reduces the incidence of hospitalizations for febrile neutropenia (FN) as well as minimizes chemotherapy dose reductions and delays that could compromise treatment outcomes. In...

  • Early G-CSF reduces febrile neutropenia/death from infection.  // Reactions Weekly;5/28/2005, Issue 1053, p5 

    Presents a study on the effects of the early administration of granulocyte colony stimulating factors (G-CSF) on cancer patients receiving chemotherapy, published in the May 15, 2005 issue of the journal "Awareness of Neutropenia in Chemotherapy." Number of patients involved in the study;...

  • Effects of a Reduced Dose of Pegfilgrastim on the Incidence of Febrile Neutropenia and Bone Pain: A Retrospective Analysis. Iacovelli, Lew; Harms, Richard; Mo, May // Journal of Hematology Oncology Pharmacy;Sep2012, Vol. 2 Issue 3, p76 

    Background: Pegfilgrastim 6 mg given 24 hours after chemotherapy reduces the incidence of febrile neutropenia (FN) in patients with nonmyeloid malignancies. Some clinicians have advocated reduced doses of pegfilgrastim to decrease the risk of pegfilgrastim-associated bone pain. Objective: To...

  • Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Gupta, Seema; Singh, Pankaj K.; Bhatt, Madan L. B.; Pant, Mohan C.; Gupta, Rajeev; Negi, Mahendra P. S. // BioScience Trends;Oct2010, Vol. 4 Issue 5, p273 

    Secondary prophylaxis with recombinant human granulocyte colony stimulating factor (G-CSF) is recommended where patients have experienced febrile neutropenia in an earlier chemotherapy cycle and for whom the maintenance of chemotherapy dose intensity is important; or where febrile neutropenia...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics